Gelonghui August 28th | Meike Pharma (688373.SH) released its 2024 interim report, with revenue of 60.738 million yuan, a year-on-year increase of 44.24%; net income attributable to the company's shareholders amounted to -0.201 billion yuan.
盟科药业(688373.SH)：上半年净亏损2.01亿元
Mengke Pharmaceutical (688373.SH): net loss of 201 million yuan in the first half of the year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.